A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Southampton doctors trial new gel-beads to treat fibroids

Description
Doctors in Southampton are trialling the use of new dissolvable gel-beads to treat fibroids in a world-first study.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2018/March-2018/Southampton-doctors-trial-new-gel-beads-to-treat-fibroids.aspx

Records management policy

Description
Records Management Policy Date Issued: Review Date: Document Type: 9 May 2018 19 April 2021 Policy Version: 6 Contents Paragraph 1 2 3 3.1 3.2 3.3 3.
Url
/Media/UHS-website-2019/Docs/Policies/Records-management-policy.pdf

Join us to review plans for a new park and ride and health campus

Description
We invite you to join us for an opportunity to review, discuss and feedback on the latest plans for a permanent staff park and ride facility and new health campus based at Adanac Park. The event will be held on Monday, 14 January at Nursling and Rownhams Village Hall.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2019/January/Join-us-to-review-plans-for-a-new-park-and-ride-and-health-campus.aspx

New park and ride and health campus plans go on display

Description
Plans for a permanent staff park and ride facility serving University Hospital Southampton NHS Foundation Trust and a new health campus, both to be based at Adanac Park, Nursling, will go on display at two public events tomorrow (Wednesday). UHS has been working with commercial estates development partner Prime and architects Stride Treglown on a design concept for the site which people will be able to learn more about, offer feedback on and discuss with members of the project team. The first event will take place in the main entrance at Southampton General Hospital from 9am until 1.30pm, with a second drop-in session to be held at Lordshill Community Centre on Cromarty Road from 2.30pm until 7.30pm. A separate planning application for a temporary staff park and ride facility has been submitted in recent weeks, but the plans being displayed tomorrow – which have not yet been submitted – will outline proposals for a permanent development to replace the temporary facility once its lease comes to an end. The accompanying health campus facility would provide a group of buildings for use by UHS and other healthcare organisations for purposes such as clinical facilities, training centres or administrative spaces. If you are unable to attend either event but would like more information about the proposed scheme, email adanacpark@primeplc.com .
Url
/AboutTheTrust/Newsandpublications/Latestnews/2018/September-2018/New-park-and-ride-and-health-campus-plans-go-on-display.aspx

Southampton researchers use heart drug to treat eye disease in groundbreaking study

Description
Researchers in Southampton are leading a groundbreaking study into whether or not a drug used to treat heart failure could save the sight of patients with a currently untreatable eye condition.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2017/April-2017/Southampton-researchers-use-heart-drug-to-treat-eye-disease-in-groundbreaking-study.aspx

Lung stereotactic ablative body radiotherapy (SABR) - patient information

Description
This factsheet explains what lung stereotactic ablative body radiotherapy (SABR) is and what to expect during treatment.
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Lung-stereotactic-ablative-body-radiotherapy-SABR-2091-PIL.pdf

Follow up after breast cancer - patient information

Description
This booklet explains what self-supported management is after treatment for early breast cancer and how it works.
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Follow-up-after-breast-cancer-1107-PIL.pdf

Moving to another care provider - patient information

Description
This factsheet explains what will happen when you leave hospital and move to a temporary or permanent care placement with a care provider.
Url
/Media/UHS-website-2019/Patientinformation/Visitinghospital/Moving-to-another-care-provider-3431-PIL.pdf

Carotid endarterectomy - patient information

Description
Information about having a carotid endarterectomy
Url
/Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Carotid-endarterectomy-1656-PIL.pdf

Tarlatamab (EAMS)

Description
Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) Tarlatamab (EAMS) Regimen • SCLC – Tarlatamab (EAMS) Indication • Tarlatamab is indicated as monotherapy for the treatment of adult patients with advanced Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy. • This is currently an unlicensed drug in the UK, being supplied and administer under a manufacturer’s Expanded Access Program, on a named-patient basis. Toxicity Drug Tarlatamab Adverse Effect Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Tumour Lysis Syndrome (TLS), hypersensitivity reactions, fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, constipation, nausea, anaemia, neutropenia, thrombocytopenia, lymphopenia, hepatotoxicity, decreased sodium and increased uric acid The adverse effects listed are not exhaustive. Please refer to the relevant summary of product characteristics for further details. Risk of tumour lysis syndrome (TLS) may be increased in patients with a high tumour burden and rapidly growing tumour. Please follow the relevant hospital guidelines for the assessment, prophylaxis and management of TLS when required. Severe CRS and ICANS can occur with Tarlatamab. For assessment and management of CRS and ICANS, please refer to the following hospital guidelines: • Assessment and management of Cytokine Release Syndrome (CRS) following CART Therapy. • Diagnosis and management of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) POST CAR-T Therapy. • Immune Effector Cells including CAR-T cells policy. Version 1.0 (February 2025) Page 1 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS Pre-Assessment • Record height and weight & performance status (ECOG). • Blood tests: FBC, U&Es, Ca2+ and LFTs at baseline and prior to each dose of treatment. • Consent and counselling - ensure patient has received adequate verbal and written information regarding their disease, treatment, and potential side effects. Document in medical notes all information that has been given. Obtain written consent prior to treatment. • Treatment should be agreed in the relevant MDT. Monitoring • It is advisable to admit patients as an inpatient during the step-up dosing period (Cycle 1, days 1 and 8) due to the risk of cytokine release syndrome (CRS) and Immune-Effector Cell Associated Neurotoxic Syndrome (ICANS). • Follow monitoring recommendations detailed on “Protocol” section below, during and after each Tarlatamab administration. Dose Modifications No dose reductions for Tarlatamab are recommended. Please see the recommended actions on the tables below Any treatment changes should be discussed with the relevant consultant before prescribing if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Haematological Consider blood transfusion or the use of erythropoietin according to NICE TA323 if patient symptomatic of anaemia or has haemoglobin of less than 8g/dL (80g/L). Table 1 Neutrophils (x109 /L) Actions Less than 1.0 or Febrile neutropenia Withhold Tarlatamab until neutrophil count improves to at least 1.0 x109 /L and fever resolves. Consider administration of granulocyte colony stimulating factor (GCSF) Permanently discontinue if recovery does not occur within 3 weeks. Recurrent grade 4 Permanently discontinue Tarlatamab neutropenia (less than 0.5) Platelets (x109 /L) Actions Less than 50 Withhold Tarlatamab until platelet count improves to at least 50 x109 /L and no evidence of bleeding. Permanently discontinue if recovery does not occur within 3 weeks. Version 1.0 (February 2025) Page 2 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS Recurrent grade 4 thrombocytopenia (less than 25) Haemoglobin (x g/dL) Less than 8 Permanently discontinue Tarlatamab Actions Withhold Tarlatamab until haemoglobin level improves to at least 8 g/dL Hepatic Impairment Table 2 Severity Actions Grade 1 or 2 ALT/AST ( 5.0 20.0 x ULN) Withhold Tarlatamab until toxicity improves to ≤ Grade 1. OR Grade 3 increased Bilirubin (> 3.0 - 10.0 x ULN) Grade 4 increased ALT or AST (> 20.0 x ULN) Permanently discontinue Tarlatamab OR Grade 4 increased Bilirubin (> 10.0 x ULN) OR AST or ALT > 3 × ULN with total bilirubin > 2 × ULN in the absence of alternative causes Renal Impairment Table 3 Severity CrCl > 30 mL/min CrCl 6 L/min Withhold Tarlatamab until adverse reaction resolves, then resume at the next scheduled dose. When resuming treatment at the next planned dose, monitor patient from the start of the Tarlatamab infusion for 24 hours in an appropriate healthcare setting. See “Assessment and Management of Cytokine Release Syndrome (CRS) following CAR-T Therapy”. Grade 3 Severe symptoms defined as Recurrent or duration of more than 48 hours Temperature ≥38°C with either Hypotension requiring one vasopressor with or without vasopressin. OR Oxygen requirement of > 6 L/min Grade 4 Temperature ≥38°C with either Hypotension requiring multiple vasopressor (excluding vasopressin) OR Withhold Tarlatamab until adverse reaction resolves, then resume at the next scheduled dose. For recurrent Grade 3 events, permanently discontinue Tarlatamab. When resuming treatment at the next planned dose, monitor patient from the start of the Tarlatamab infusion for 24 hours in an appropriate healthcare setting. See “Assessment and Management of Cytokine Release Syndrome (CRS) following CAR-T Therapy”. Permanently discontinue Tarlatamab. See “Assessment and Management of Cytokine Release Syndrome (CRS) following CAR-T Therapy”. Version 1.0 (February 2025) Page 4 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS Oxygen requirement of positive pressure (i.e. CPAP, BiPAP, intubation, and mechanical ventilation) ICANS Grade 1 ICE score 7-9b with no depressed level of consciousness. Grade 2 ICE score 3-6b and/or mild somnolence awaking to voice. Grade 3 ICE score 0-2 AND/OR depressed level of consciousness awakening only to tactile stimulus. AND/OR Any clinical seizure focal or generalized that resolves rapidly or nonconvulsive seizures on EEG that resolve with intervention. AND/OR Focal or local oedema on neuroimaging. Actions Withhold Tarlatamab until adverse reaction resolves, then resume at the next scheduled dose. See “Diagnosis and Management of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) POST CAR-T Therapy”. Withhold Tarlatamab until adverse reaction resolves, then resume at the next scheduled dose. When resuming treatment at the next planned dose, monitor patient from the start of the Tarlatamab infusion for 24 hours in an appropriate healthcare setting. See “Diagnosis and Management of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) POST CAR-T Therapy”. Withhold Tarlatamab until adverse reaction resolves, then resume at the next scheduled dose. If no improvement to grade ≤ 1 within 7 days or recurrent grade 3 toxicity, permanently discontinue Tarlatamab. Recommended intensive monitoring (ICU care). When resuming treatment at the next planned dose, monitor patient from the start of the Tarlatamab infusion for 24 hours in an appropriate healthcare setting. See “Diagnosis and Management of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) POST CAR-T Therapy”. Grade 4 ICE score 0 (patient is unarousable and unable to perform ICE); AND/OR Stupor or coma; AND/OR Life-threatening prolonged seizure (> 5 minutes) or repetitive clinical or electrical seizures without return to baseline in between; AND/OR diffuse cerebral oedema on Version 1.0 (February 2025) Permanent discontinuation. ICU care. Treat convulsive status epilepticus as per local guidelines. See “Diagnosis and Management of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) POST CAR-T Therapy”. Page 5 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS neuroimaging, decerebrate or decorticate posturing or papilledema, cranial nerve VI palsy, or Cushing’s triad. Other Adverse Reactions Grade 3 and 4 Actions Withhold Tarlatamab until recovery to ≤Grade 1 or baseline. Consider permanently discontinuing if adverse reaction does not resolve within 28 days. Consider permanent discontinuation for Grade 4 events. Hypersensitivity reactions Hypersensitivity reactions have been reported in patients treated with tarlatamab including rare severe events. Clinical signs and symptoms of hypersensitivity may include but are not limited to rash and bronchospasm. Monitor patients for signs and symptoms of hypersensitivity during treatment with tarlatamab and manage as clinically indicated. Withhold or consider permanent discontinuation of tarlatamab based on severity. Regimen 28 day cycle until disease progression or intolerable Toxicity (12 cycles will be set on ARIA) Table 5 Dosing schedule Cycle 1a Day 1 Day 8 Day 15 Dose 1mg step-up dose 10mg 10mg Monitoring Monitor patients from the start of the infusion for 24 hours in an appropriate healthcare setting. Recommend that patients remain within 1-hour of an appropriate healthcare setting for a total of 48 hours from start of the infusion accompanied by a caregiver. Observe patients for 6-8 hours post infusion Cycle 2 Cycles 3 and 4 Cycle 5 and subsequent cycles Day 1 and 15 Day 1 and 15 Day 1 and 15 10mg 10mg 10mg Observe patients for 6-8 hours post infusionb Observe patients for 3-4 hours post infusion b Observe patients for 2 hours post infusion b a Administer recommended concomitant medications before and after Cycle 1 Tarlatamab infusions as described on Table 7. b Extended monitoring in a healthcare setting is not required unless the patient experiences Grade ≥2 CRS, ICANS or neurological toxicity during prior treatments. See Table 4 for monitoring recommendations. Note: see Table 6 for recommendation on restarting tarlatamab after dose delays. Version 1.0 (February 2025) Page 6 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS Dose Information • Tarlatamab is available as 1mg and 10mg of lyophilised powder in single-dose vials for reconstitution and further dilution. • If a dose of Tarlatamab is delayed, treatment should be resumed based on the recommendations listed on the table below. Administer recommended concomitant medications as indicated below [see Additional therapy] and monitor patients accordingly [see Regimen]. Table 6 Last Dose Administered 1 mg on Cycle 1 Day 1 10 mg on Cycle 1 Day 8 10 mg on Cycle 1 Day 15 and subsequent Cycles every 2 weeks thereafter Time Since the Last Dose Administered 14 days or less Over 14 days 21 days or less Over 21 days 28 days or less Over 28 days Action Administer Tarlatamab 10 mg, then resume with the planned dosage schedule. Administer Tarlatamab step-up dose 1 mg. If tolerated, increase to 10 mg 1 week later. Then resume with the planned dosage schedule. Administer Tarlatamab 10 mg, then resume with the planned dosage schedule. Administer Tarlatamab step-up dose 1 mg. If tolerated, increase to 10 mg 1 week later. Then resume with the planned dosage schedule. Administer Tarlatamab 10 mg, then resume with the planned dosage schedule. Administer Tarlatamab step-up dose 1 mg. If tolerated, increase to 10 mg 1 week later. Then resume with the planned dosage schedule. Administration Information • Tarlatamab should be reconstituted and diluted in 250ml of 0.9% Sodium Chloride and administered as an intravenous infusion over 1 hour at a constant flow rate using an infusion pump. • The intravenous (IV) catheter used for concomitant medications administration can be used to administer the tarlatamab infusion. • To ensure patency, flush the IV catheter over 3-5 mins using 0.9% Sodium Chloride for Injection. Version 1.0 (February 2025) Page 7 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS Additional Therapy • Dexamethasone 8mg IV (or equivalent) and Sodium Chloride 0.9% must be administered on Cycle 1, as per table below: Table 7 Additional medication Cycle 1 Cycle 1 Cycle 1 day 1 day 8 day 15 Dexamethasone 8mg intravenous injection 1 hour √ √ prior to Tarlatamab infusion Sodium chloride 0.9% 1000ml intravenous infusion over 60 minutes, starting immediately after √ √ √ completion of Tarlatamab infusion • Premedication may also be required if: - Patients who repeat the step-up dosing after delays. - Patients who experienced CRS or other infusion reactions in the previous dose. • Tocilizumab must be prescribed as when required in advance of Tarlatamab infusion, in the event of CRS.Tocilizumab (8 mg/kg, maximum dose 800 mg) intravenously 8hourly if required. See Assessment and Management of Cytokine Release Syndrome (CRS) following CAR-T Therapy. - One dose of tocilizumab must be available on the ward or pre-specified location prior to infusion of Tarlatamab. - Follow local procedures for administration. • Tumour lysis syndrome (TLS) prophylaxis should be prescribed according to the individual patient TLS risk and at consultant review: - In high-risk patients, consider 3 mg rasburicase intravenous once prior to first dose Tarlatamab followed by oral allopurinol 300 mg once daily starting the day after rasburicase. - For low to moderate risk patients, start allopurinol 300 mg oral (100 mg if renal impairment) - This must be assessed prior to Tarlatamab treatment and at each dose increment. • In the event of Tarlatamab hypersensitivity reactions: - hydrocortisone 100mg intravenous when required for the relief of Tarlatamab infusion related reactions. - salbutamol 2.5mg nebule when required for Tarlatamab related bronchospasm. References Version 1.0 (February 2025) Page 8 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS BC Cancer Provincial Health Services Authority. Tarlatamab (interim monograph). BC Cancer 2024. Available from: http://www.bccancer.bc.ca/drug-databasesite/Drug%20Index/Tarlatamab_interim%20monograph.pdf U.S. Food and Drug Administration (FDA). IMDELLTRA™ (tarlatamab-dlle). FDA 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf Version 1.0 (February 2025) Page 9 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS REGIMEN SUMMARY Tarlatamab (EAMS) Cycle 1 Day 1 1. Warning – Ensure TLS assessment completed. - TLS prophylaxis allopurinol supplied as pick-up internal on day 1. - Rasburicase if required will need prescribing on Aria internal prescription. 2. Dexamethasone 8mg intravenous injection Admin Instructions: To be administered 60 minutes prior to Tarlatamab. 3. Tarlatamab 1mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Monitor patients from the start of the infusion for 24 hours. It is recommended that patients remain within 1-hour of an appropriate healthcare setting for a total of 48 hours from the start of the infusion accompanied by a caregiver. 4. Sodium chloride 0.9% 1000ml intravenous infusion over 300 minutes Admin instructions: to be administered immediately after completion of Tarlatamab infusion. 5. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 6. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm 7. Tocilizumab 8mg/kg (maximum 800mg) intravenous 8-hourly if required in the event of CRS. Maximum 3 doses. Administration Instructions See Trust Protocol for CRS management post Tarlatamab. One dose of tocilizumab must be available on the ward or pre-specified location prior to infusion of Tarlatamab. Follow local procedures for administration Take home medicines (Day 1) 8. Allopurinol 300mg oral once a day for 28 days. In accordance with patient assessment. Day 8 9. Warning – Ensure TLS assessment completed. - TLS prophylaxis allopurinol supplied as pick-up internal on day 1. - Rasburicase if required will need prescribing on Aria internal prescription. 10. Dexamethasone 8mg intravenous injection Admin Instructions: To be administered 60 minutes prior to Tarlatamab. 11. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Monitor patients from the start of the infusion for 24 hours. It is recommended that patients remain within 1-hour of an appropriate healthcare setting for a total of 48 hours from the start of the infusion accompanied by a caregiver. 12. Sodium chloride 0.9% 1000ml intravenous infusion over 300 minutes Admin instructions: to be administered immediately after completion of Tarlatamab infusion. Version 1.0 (February 2025) Page 10 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS 13. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 14. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm 15. Tocilizumab 8mg/kg (maximum 800mg) intravenous 8-hourly if required in the event of CRS. Maximum 3 doses. Administration Instructions See Trust Protocol for CRS management post Tarlatamab. One dose of tocilizumab must be available on the ward or pre-specified location prior to infusion of Tarlatamab. Follow local procedures for administration. Day 15 16. Warning – Ensure TLS assessment completed. - TLS prophylaxis allopurinol supplied as pick-up internal from Day 1. - Rasburicase if required will need prescribing on in-patient prescribing system 17. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 6-8 hours post infusion. 18. Sodium chloride 0.9% 1000ml intravenous infusion over 300 minutes Admin instructions: to be administered immediately after completion of Tarlatamab infusion. 19. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 20. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm Cycle 2 Day 1 21. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 6-8 hours post infusion. 22. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 23. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm Day 15 24. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 6-8 hours post infusion. 25. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 26. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm Version 1.0 (February 2025) Page 11 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS Cycle 3 Day 1 27. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 3-4 hours post infusion. 28. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 29. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm Day 15 30. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 3-4 hours post infusion. 31. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 32. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm Cycle 4 Day 1 33. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 3-4 hours post infusion. 34. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 35. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm Day 15 36. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 3-4 hours post infusion. 37. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 38. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm Cycle 5 onwards Day 1 39. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 2 hours post infusion. Version 1.0 (February 2025) Page 12 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS 40. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 41. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm Day 15 42. Tarlatamab 10mg intravenous infusion in 250ml sodium chloride 0.9% over 1 hour Admin Instructions: Observe patients for 2 hours post infusion. 43. Hydrocortisone 100mg intravenous once only when required for the relief of Tarlatamab infusion related reactions 44. Salbutamol 2.5mg nebule once only when required for the relief of Tarlatamab related bronchospasm DOCUMENT CONTROL Version Date Amendment Written By Approved By 1.0 07 February 2025 Alexandre Guedes (Pharmacist) Dr Judith Cave This chemotherapy protocol has been developed as part of the chemotherapy electronic prescribing project. This was and remains a collaborative project that originated from the former CSCCN. These documents have been approved on behalf of the following Trusts; Hampshire Hospitals NHS Foundation Trust NHS Isle of Wight Portsmouth Hospitals NHS Trust Salisbury Hospital NHS Foundation Trust University Hospital Southampton NHS Foundation Trust Western Sussex Hospitals NHS Foundation Trust All actions have been taken to ensure these protocols are correct. However, no responsibility can be taken for errors that occur as a result of following these guidelines. Version 1.0 (February 2025) Page 13 of 13 Lung cancer (Small Cell) – Tarlatamab EAMS
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Tarlatamab-EAMS-Ver-1.0.pdf
1 to 10 of 201
Previous 1 2 3 4 5 … Next